{"id":908485,"date":"2025-11-11T09:56:16","date_gmt":"2025-11-11T14:56:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/"},"modified":"2025-11-11T09:56:16","modified_gmt":"2025-11-11T14:56:16","slug":"sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/","title":{"rendered":"SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">BOSTON<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 11, 2025<\/span><\/span> \/PRNewswire\/ &#8212; <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4554279-1&amp;h=1310327778&amp;u=https%3A%2F%2Fwww.completegenomics.com%2F&amp;a=Complete+Genomics\" target=\"_blank\" rel=\"nofollow\">Complete Genomics<\/a>, a leading innovator in genomic sequencing, today announced a collaboration with <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4554279-1&amp;h=3493247899&amp;u=https%3A%2F%2Fwww.sophiagenetics.com%2F&amp;a=SOPHiA+GENETICS\" target=\"_blank\" rel=\"nofollow\">SOPHiA GENETICS<\/a> (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS\u00ae and MSK-IMPACT\u00ae powered with SOPHiA DDM\u2122 on Complete Genomics&#8217; DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to customers globally. The announcement was made from the <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4554279-1&amp;h=1865913025&amp;u=https%3A%2F%2Famp25.amp.org%2F&amp;a=Association+for+Molecular+Pathology+(AMP)+Annual+Meeting\" target=\"_blank\" rel=\"nofollow\">Association for Molecular Pathology (AMP) Annual Meeting<\/a> in <span class=\"xn-location\">Boston<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1673202\/SOPHiA_GENETICS_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1673202\/SOPHiA_GENETICS_Logo.jpg\" title=\"SOPHiA GENETICS Logo (PRNewsfoto\/SOPHiA GENETICS)\" alt=\"SOPHiA GENETICS Logo (PRNewsfoto\/SOPHiA GENETICS)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>The collaboration integrates SOPHiA GENETICS&#8217; advanced, AI-powered applications <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4554279-1&amp;h=3995850631&amp;u=https%3A%2F%2Fwww.sophiagenetics.com%2Fmsk-impact-powered-with-sophia-ddm%2F&amp;a=MSK-IMPACT%C2%AE\" target=\"_blank\" rel=\"nofollow\">MSK-IMPACT\u00ae<\/a>\u00a0and <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4554279-1&amp;h=1692125652&amp;u=https%3A%2F%2Fwww.sophiagenetics.com%2Fsophia-ddm-for-genomics%2Fliquid-biopsy%2Fmsk-access%2F&amp;a=MSK-ACCESS%C2%AE\" target=\"_blank\" rel=\"nofollow\">MSK-ACCESS\u00ae<\/a>\u00a0powered by SOPHiA DDM\u2122, developed in collaboration with Memorial Sloan Kettering Cancer Center\u00a0(MSK), with Complete Genomics&#8217; newly launched DNBSEQ-T1+ sequencing platform. Together, Complete Genomics and SOPHiA GENETICS will provide an integrated, sample-to-report workflow for laboratories, marking a significant expansion of their partnership into the precision oncology research market.<\/p>\n<p>&#8220;Pairing MSK-IMPACT\u00ae and MSK-ACCESS\u00ae powered with SOPHiA DDM\u2122 with our DNBSEQ-T1+ platform creates a powerful and accessible solution for laboratories looking to scale high-quality cancer genomic profiling,&#8221; said <span class=\"xn-person\">Rob Tarbox<\/span>, vice president of product and marketing at Complete Genomics. &#8220;By combining MSK&#8217;s rigorously validated assays, SOPHiA GENETICS&#8217; robust analytics, and our sequencing technology, we are enabling <span>decentralized<\/span> labs to deliver faster, more accurate, and more affordable insights to clinicians and researchers.&#8221;<\/p>\n<p>&#8220;This collaboration underscores SOPHiA GENETICS&#8217; commitment to broadening access to data-driven medicine,&#8221; said <span class=\"xn-person\">Ross Muken<\/span>, President,\u00a0SOPHiA GENETICS. &#8220;Partnering with Complete Genomics to streamline use of MSK-IMPACT\u00ae and MSK-ACCESS\u00ae powered with SOPHiA DDM\u2122 on the DNBSEQ-T1+ platform enables more laboratories around the world to adopt precision oncology through scalable, end-to-end genomic solutions.&#8221;<\/p>\n<p>The DNBSEQ-T1+, powered by proprietary DNBSEQ technology, delivers Q40-level accuracy, optimized throughput from 500 million to 2 billion reads per flow cell. Each flow cell is able to be run independently, with a 24-hour paired-end 150bp run time, offering laboratories a cost-effective and highly flexible sequencing solution. At maximum throughput, each T1+ flow cell can run up to 60 tumor-normal sample pairs for tissue, up to 16 tumor-normal sample pairs for liquid biopsy.<\/p>\n<p>SOPHiA DDM\u2122 is a technology-agnostic analytics platform that leverages AI to compute, standardize, and analyze healthcare data. Joint evaluation of <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4554279-1&amp;h=3995850631&amp;u=https%3A%2F%2Fwww.sophiagenetics.com%2Fmsk-impact-powered-with-sophia-ddm%2F&amp;a=MSK-IMPACT%C2%AE\" target=\"_blank\" rel=\"nofollow\">MSK-IMPACT\u00ae<\/a> and <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4554279-1&amp;h=1692125652&amp;u=https%3A%2F%2Fwww.sophiagenetics.com%2Fsophia-ddm-for-genomics%2Fliquid-biopsy%2Fmsk-access%2F&amp;a=MSK-ACCESS%C2%AE\" target=\"_blank\" rel=\"nofollow\">MSK-ACCESS\u00ae<\/a> on the DNBSEQ-T1+ platform demonstrated highly concordant variant calls and allele frequencies compared with equivalent sequencing systems, while achieving lower background noise, reduced turnaround time, and seamless compatibility with existing SOPHiA DDM\u2122 workflows.<\/p>\n<p>This new offering provides clinical laboratories, cancer centers, and drug developers with a high-performance, cost-efficient path to implementing comprehensive genomic profiling for precision oncology research.<\/p>\n<p>To learn more, visit the Complete Genomics Booth 1210 or SOPHiA GENETICS Booth 921 at AMP from November 11\u201315, 2025 or visit <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4554279-1&amp;h=1988000373&amp;u=http%3A%2F%2Fwww.completegenomics.com%2F&amp;a=www.CompleteGenomics.com\" target=\"_blank\" rel=\"nofollow\">www.CompleteGenomics.com<\/a> and <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4554279-1&amp;h=342036025&amp;u=http%3A%2F%2Fwww.sophiagenetics.com%2F&amp;a=www.SOPHiAGENETICS.com\" target=\"_blank\" rel=\"nofollow\">www.SOPHiAGENETICS.com<\/a>.<\/p>\n<p>\n        <b>About Complete Genomics<br \/><\/b>Complete Genomics is a pioneering life sciences company that provides novel, complete sequencing solutions including sample\/library preparation, lab automation, sequencing, and data analysis. The sequencing portfolio offers a full lineup of sequencers ranging from low, medium, and high throughput capacities, all powered by its proprietary DNBSEQ technology. More than 10,900 publications are based on DNBSEQ technology across a wide array of applications. To learn more, visit <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4554279-1&amp;h=1692852036&amp;u=http%3A%2F%2Fwww.completegenomics.com%2F&amp;a=www.completegenomics.com\" target=\"_blank\" rel=\"nofollow\">www.completegenomics.com<\/a>.<\/p>\n<p>\n        <i>* For Research Use Only. Not for use in diagnostic procedures.<\/i>\n      <\/p>\n<p>\n        <b>About SOPHiA GENETICS<\/b>\u00a0\u00a0<br \/>SOPHiA GENETICS (Nasdaq:\u00a0<b><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4554279-1&amp;h=2325203176&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fsophia-genetics-launches-ai-powered-digital-twins-to-enhance-intelligent-decision-making-in-oncology-302585690.html%23financial-modal&amp;a=SOPH\" target=\"_blank\" rel=\"nofollow\">SOPH<\/a><\/b>) is a\u00a0cloud-native healthcare technology\u00a0company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients\u00a0with cancer and rare disorders\u00a0across the globe. It is the creator of the SOPHiA DDM\u2122 Platform, which\u00a0analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.\u00a0\u00a0For more information, visit <b><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4554279-1&amp;h=3599272380&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4534088-1%26h%3D3379755616%26u%3Dhttps%253A%252F%252Fwww.sophiagenetics.com%252F%26a%3DSOPHiAGENETICS.COM&amp;a=SOPHiAGENETICS.COM\" target=\"_blank\" rel=\"nofollow\">SOPHiAGENETICS.COM<\/a><\/b>and connect with us on\u00a0<b><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4554279-1&amp;h=1303074081&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4534088-1%26h%3D1957023279%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fsophiagenetics%252F%26a%3DLinkedIn&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a><\/b>.\u00a0<\/p>\n<p>\n        <i>S<\/i><br \/>\n        <i>OPHiA DDM\u2122 is for<\/i>\u00a0<i>Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact\u00a0<\/i><b><i><a href=\"mailto:support@sophiagenetics.com\" target=\"_blank\" rel=\"nofollow\">support@sophiagenetics.com<\/a><\/i><\/b>\u00a0<i>to obtain the appropriate product information for your country of residence.<\/i>\u00a0<\/p>\n<p>\n        <b><br \/>\n          <i>SOPHiA GENETICS Forward-Looking Statements:\u00a0<\/i><br \/>\n        <\/b><br \/>\n        <br \/>\n        <i>This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.<\/i>\u00a0\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=NE20311&amp;sd=2025-11-11\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine-302610620.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine-302610620.html<\/a><\/p>\n<p>SOURCE  SOPHiA GENETICS<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE20311&amp;Transmission_Id=202511110900PR_NEWS_USPR_____NE20311&amp;DateId=20251111\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire BOSTON , Nov. 11, 2025 \/PRNewswire\/ &#8212; Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS\u00ae and MSK-IMPACT\u00ae powered with SOPHiA DDM\u2122 on Complete Genomics&#8217; DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to customers globally. The announcement was made from the Association for Molecular Pathology (AMP) Annual Meeting in Boston. The collaboration integrates SOPHiA GENETICS&#8217; advanced, AI-powered applications MSK-IMPACT\u00ae\u00a0and MSK-ACCESS\u00ae\u00a0powered by SOPHiA DDM\u2122, developed in collaboration with Memorial Sloan Kettering Cancer Center\u00a0(MSK), with Complete Genomics&#8217; newly launched DNBSEQ-T1+ sequencing platform. Together, Complete &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-908485","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire BOSTON , Nov. 11, 2025 \/PRNewswire\/ &#8212; Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS\u00ae and MSK-IMPACT\u00ae powered with SOPHiA DDM\u2122 on Complete Genomics&#8217; DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to customers globally. The announcement was made from the Association for Molecular Pathology (AMP) Annual Meeting in Boston. The collaboration integrates SOPHiA GENETICS&#8217; advanced, AI-powered applications MSK-IMPACT\u00ae\u00a0and MSK-ACCESS\u00ae\u00a0powered by SOPHiA DDM\u2122, developed in collaboration with Memorial Sloan Kettering Cancer Center\u00a0(MSK), with Complete Genomics&#8217; newly launched DNBSEQ-T1+ sequencing platform. Together, Complete &hellip; Continue reading &quot;SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-11T14:56:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1673202\/SOPHiA_GENETICS_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine\",\"datePublished\":\"2025-11-11T14:56:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\\\/\"},\"wordCount\":922,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1673202\\\/SOPHiA_GENETICS_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\\\/\",\"name\":\"SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1673202\\\/SOPHiA_GENETICS_Logo.jpg\",\"datePublished\":\"2025-11-11T14:56:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1673202\\\/SOPHiA_GENETICS_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1673202\\\/SOPHiA_GENETICS_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/","og_locale":"en_US","og_type":"article","og_title":"SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine - Market Newsdesk","og_description":"PR Newswire BOSTON , Nov. 11, 2025 \/PRNewswire\/ &#8212; Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS\u00ae and MSK-IMPACT\u00ae powered with SOPHiA DDM\u2122 on Complete Genomics&#8217; DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to customers globally. The announcement was made from the Association for Molecular Pathology (AMP) Annual Meeting in Boston. The collaboration integrates SOPHiA GENETICS&#8217; advanced, AI-powered applications MSK-IMPACT\u00ae\u00a0and MSK-ACCESS\u00ae\u00a0powered by SOPHiA DDM\u2122, developed in collaboration with Memorial Sloan Kettering Cancer Center\u00a0(MSK), with Complete Genomics&#8217; newly launched DNBSEQ-T1+ sequencing platform. Together, Complete &hellip; Continue reading \"SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-11T14:56:16+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1673202\/SOPHiA_GENETICS_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine","datePublished":"2025-11-11T14:56:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/"},"wordCount":922,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1673202\/SOPHiA_GENETICS_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/","name":"SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1673202\/SOPHiA_GENETICS_Logo.jpg","datePublished":"2025-11-11T14:56:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1673202\/SOPHiA_GENETICS_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1673202\/SOPHiA_GENETICS_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sophia-genetics-and-complete-genomics-integrate-sequencing-and-ai-analytics-to-accelerate-adoption-of-precision-medicine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/908485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=908485"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/908485\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=908485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=908485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=908485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}